{"publisher":"KPV Peptide Rx","product":"KPV","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"The 2008 KPV paper used human cell lines and two chemically induced mouse-colitis models, not a human randomized treatment trial.","href":"https://pubmed.ncbi.nlm.nih.gov/18061177/"},{"label":"Research finding 2","text":"It linked cell uptake to PepT1 and observed reduced inflammatory signaling and cytokine outcomes in experimental systems.","href":"https://pubmed.ncbi.nlm.nih.gov/18061177/"},{"label":"Research finding 3","text":"The 2017 study tested KPV in hyaluronic-acid-functionalized nanoparticles and a hydrogel, with improved experimental colitis outcomes in mice.","href":"https://pubmed.ncbi.nlm.nih.gov/28143741/"},{"label":"Research finding 4","text":"That engineered delivery system is distinct from ordinary KPV capsules or injections; its mouse results do not establish human clinical efficacy.","href":"https://pubmed.ncbi.nlm.nih.gov/28143741/"}],"sources":[{"title":"PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.","href":"https://pubmed.ncbi.nlm.nih.gov/18061177/"},{"title":"Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.","href":"https://pubmed.ncbi.nlm.nih.gov/28143741/"},{"title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances","href":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf"}],"guides":[{"title":"KPV colitis research: what mice can and cannot answer for an IBD patient","url":"https://kpvpeptiderx.com/research-guides/colitis-models-and-patient-questions","description":"A study-design guide for people evaluating KPV claims alongside established inflammatory bowel disease care.","date":"2026-11-07"},{"title":"KPV cytokine claims: from a pathway diagram to a patient question","url":"https://kpvpeptiderx.com/research-guides/cytokine-signals-versus-symptoms","description":"Read NF-kappaB, IL-8 and other laboratory signals without treating them as established symptom relief.","date":"2026-11-07"},{"title":"A GI symptom record for a KPV consultation","url":"https://kpvpeptiderx.com/research-guides/gi-symptom-record-for-consultation","description":"Bring observations that help clinical assessment without using a diary or a peptide page to diagnose yourself.","date":"2026-11-07"},{"title":"Why oral KPV access does not establish an injectable pathway","url":"https://kpvpeptiderx.com/research-guides/injectable-kpv-access-assumptions","description":"Check the exact route in a policy document before accepting a claim that every KPV preparation is covered.","date":"2026-11-07"},{"title":"KPV acetate and a COA: connect the document to the supplied material","url":"https://kpvpeptiderx.com/research-guides/kpv-acetate-coa-identity","description":"Read identity and lot information without treating a purity number as proof of clinical effectiveness.","date":"2026-11-07"},{"title":"Keep a dated KPV access record: meetings, policy and product details","url":"https://kpvpeptiderx.com/research-guides/kpv-policy-record-and-dates","description":"Read regulatory developments in sequence without treating an advisory discussion as approval of a finished medicine.","date":"2026-11-07"},{"title":"KPV, GKPV and alpha-MSH: related names, different evidence","url":"https://kpvpeptiderx.com/research-guides/kpv-versus-alpha-msh","description":"Learn how to identify the actual peptide in a paper before applying its findings to a KPV product.","date":"2026-11-07"},{"title":"KPV versus BPC-157 for gut questions: define the comparison first","url":"https://kpvpeptiderx.com/research-guides/kpv-versus-bpc-gut-questions","description":"Build a comparison around diagnosis, route and relevant evidence rather than selecting a peptide from a broad gut-health label.","date":"2026-11-07"},{"title":"Oral KPV: why the delivery system belongs in the evidence","url":"https://kpvpeptiderx.com/research-guides/oral-kpv-formulation-bioavailability","description":"A practical guide to nanoparticles, hydrogel studies and formulation-specific human bioavailability questions.","date":"2026-11-07"},{"title":"“Registered trial” is not a KPV result: read the record","url":"https://kpvpeptiderx.com/research-guides/reading-a-kpv-clinical-trial-claim","description":"Learn which fields distinguish a planned investigation, its recruitment status and any available findings.","date":"2026-11-07"},{"title":"KPV combinations and access: read the ingredient list and the dated policy","url":"https://kpvpeptiderx.com/research-guides/single-ingredient-route-and-policy","description":"Distinguish experimental combinations from single-ingredient products and check the route-specific conditions of current access policy.","date":"2026-11-07"},{"title":"Topical KPV: separate skin-cell findings from delivery and patient outcomes","url":"https://kpvpeptiderx.com/research-guides/topical-kpv-skin-study-fit","description":"Understand what keratinocyte and skin-permeation experiments establish before applying them to a cream or a skin condition.","date":"2026-11-07"}]}